Open Access

Sialylation of FGFR1 by ST6Gal‑I overexpression contributes to ovarian cancer cell migration and chemoresistance

  • Authors:
    • Lingling Ou
    • Xiuzhen He
    • Naihua Liu
    • Yuwei Song
    • Jinyuan Li
    • Lvfen Gao
    • Xinke Huang
    • Zhendong Deng
    • Xiaoyu Wang
    • Shaoqiang Lin
  • View Affiliations

  • Published online on: January 20, 2020     https://doi.org/10.3892/mmr.2020.10951
  • Pages: 1449-1460
  • Copyright: © Ou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Fibroblast growth factor receptors (FGFRs) have been implicated in the malignant transformation and chemoresistance of epithelial ovarian cancer; however, the underlying molecular mechanisms are poorly understood. Increased sialyltransferase activity that enhances protein sialylation is an important post‑translational process promoting cancer progression and malignancy. In the present study, α2,6‑sialyltransferase (ST6Gal‑I) overexpression or knockdown cell lines were developed, and FGFR1 was examined to understand the effect of sialylation on migration and drug resistance, and the underlying mechanisms. It was identified that cells with ST6Gal‑I overexpression had increased cell viability and migratory ability upon serum deprivation. Moreover, ST6Gal‑I overexpression cells had strong resistance to paclitaxel, as demonstrated by low growth inhibition rate and cell apoptosis level. A mechanistic study showed that ST6Gal‑I overexpression induced high α2,6‑sialylation of FGFR1 and increased the expression of phospho‑ERK1/2 and phospho‑focal adhesion kinase. Further study demonstrated that the FGFR1 inhibitor PD173047 reduced cell viability and induced apoptosis; however, ST6Gal‑I overexpression decreased the anticancer effect of PD173047. In addition, ST6Gal‑I overexpression attenuated the effect of Adriamycin on cancer cells. Collectively, these results suggested that FGFR1 sialylation plays an important role in cell migration and drug chemoresistance in ovarian cancer cells.
View Figures
View References

Related Articles

Journal Cover

March 2020
Volume 21 Issue 3

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Ou, L., He, X., Liu, N., Song, Y., Li, J., Gao, L. ... Lin, S. (2020). Sialylation of FGFR1 by ST6Gal‑I overexpression contributes to ovarian cancer cell migration and chemoresistance. Molecular Medicine Reports, 21, 1449-1460. https://doi.org/10.3892/mmr.2020.10951
MLA
Ou, L., He, X., Liu, N., Song, Y., Li, J., Gao, L., Huang, X., Deng, Z., Wang, X., Lin, S."Sialylation of FGFR1 by ST6Gal‑I overexpression contributes to ovarian cancer cell migration and chemoresistance". Molecular Medicine Reports 21.3 (2020): 1449-1460.
Chicago
Ou, L., He, X., Liu, N., Song, Y., Li, J., Gao, L., Huang, X., Deng, Z., Wang, X., Lin, S."Sialylation of FGFR1 by ST6Gal‑I overexpression contributes to ovarian cancer cell migration and chemoresistance". Molecular Medicine Reports 21, no. 3 (2020): 1449-1460. https://doi.org/10.3892/mmr.2020.10951